ES2052589T3 - Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo. - Google Patents

Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo.

Info

Publication number
ES2052589T3
ES2052589T3 ES87400790T ES87400790T ES2052589T3 ES 2052589 T3 ES2052589 T3 ES 2052589T3 ES 87400790 T ES87400790 T ES 87400790T ES 87400790 T ES87400790 T ES 87400790T ES 2052589 T3 ES2052589 T3 ES 2052589T3
Authority
ES
Spain
Prior art keywords
glycoprotein
aids
viral vector
codifier
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87400790T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Guy Rautmann
Jean-Pierre Lecocq
Hobson Simon Wain
Marc Girard
Luc Montagnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Institut Pasteur
Original Assignee
Transgene SA
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26225146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2052589(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8605043A external-priority patent/FR2596771B1/fr
Application filed by Transgene SA, Institut Pasteur filed Critical Transgene SA
Application granted granted Critical
Publication of ES2052589T3 publication Critical patent/ES2052589T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION CONCIERNE A UN VECTOR VIRAL CARACTERIZADO PORQUE LLEVA POR LO MENOS: UNA PARTE DE GENOMA DE UN VIRUS, UN GEN CODIFICANTEE DE UNA DE LAS GLICOPROTEINAS (GP) DE LA ENVOLTURA DEL VIRUS RESPONSABLE DEL SIDA, ASI COMO LOS ELEMENTOS QUE GARANTIZAN LA EXPRESION DE ESTA GLICOPROTEINA EN CELULAS.
ES87400790T 1986-04-08 1987-04-08 Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo. Expired - Lifetime ES2052589T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8605043A FR2596771B1 (fr) 1986-04-08 1986-04-08 Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
FR8615106A FR2606029B2 (fr) 1986-04-08 1986-10-29 Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus

Publications (1)

Publication Number Publication Date
ES2052589T3 true ES2052589T3 (es) 1994-07-16

Family

ID=26225146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87400790T Expired - Lifetime ES2052589T3 (es) 1986-04-08 1987-04-08 Vector viral, codificante para una glicoproteina del virus responsable del sida, vacuna y anticuerpo.

Country Status (12)

Country Link
EP (1) EP0245136B1 (es)
JP (3) JP2719917B2 (es)
KR (1) KR960001819B1 (es)
AT (1) ATE103328T1 (es)
AU (1) AU604696B2 (es)
CA (1) CA1341353C (es)
DE (1) DE3789400T2 (es)
DK (1) DK175613B1 (es)
ES (1) ES2052589T3 (es)
FR (1) FR2606029B2 (es)
PT (1) PT84640B (es)
WO (1) WO1987006260A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0897987B1 (en) * 1989-10-24 2001-02-28 Chiron Corporation Secretion of human protein linked to gamma interferon signal peptide
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6228608B1 (en) * 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
GB9215233D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
CN1304580C (zh) * 2004-07-09 2007-03-14 楼伟 重组表达人获得性免疫缺陷病毒I型的表面糖蛋白gp160
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
IL82104A0 (en) * 1986-04-08 1987-10-30 Usa Recombinant vaccinia virus expressing human retrovirus genes and method for producing htlb-iii envelope proteins

Also Published As

Publication number Publication date
KR880701283A (ko) 1988-07-26
DK175613B1 (da) 2004-12-27
DE3789400D1 (de) 1994-04-28
FR2606029B2 (fr) 1989-02-03
JP2719917B2 (ja) 1998-02-25
EP0245136B1 (fr) 1994-03-23
AU7234987A (en) 1987-11-09
KR960001819B1 (en) 1996-02-05
PT84640B (pt) 1989-11-30
FR2606029A2 (fr) 1988-05-06
JPH1059868A (ja) 1998-03-03
EP0245136A1 (fr) 1987-11-11
DK641787A (da) 1987-12-07
ATE103328T1 (de) 1994-04-15
AU604696B2 (en) 1991-01-03
PT84640A (fr) 1987-05-01
JP2743164B2 (ja) 1998-04-22
DE3789400T2 (de) 1994-09-01
DK641787D0 (da) 1987-12-07
JPH08224090A (ja) 1996-09-03
CA1341353C (fr) 2002-04-02
WO1987006260A1 (fr) 1987-10-22
JPH01500161A (ja) 1989-01-26

Similar Documents

Publication Publication Date Title
KR960001819B1 (en) Viral vector coding for a glycoprotein of the virus responsible
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
ES2002490A6 (es) Un metodo de preparar un virus recombinante
CA2243570A1 (en) Mixture of recombinant vaccinia vectors as polyenv vaccines for hiv
ES2053413T3 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
CO4960659A1 (es) Vacuna que comprende un antigeno de virus de la hepatitis b y un antigeno del virus herpes simplex
AR248045A1 (es) Procedimiento para producir un virus de avipox recombinante, un cultivo de celulas eucariotica, una vacuna y para expresar la totalidad o parte de una proteina heterologa, secuencia de transferencia
ES2153654T3 (es) Vectores retrovirales.
MXPA96005662A (es) Vacunas de papilomavirus.
ES2052478T1 (es) Particulas retrovirales no replicantes producidas de forma recombinante empleadas como agentes antivirales e inmunogenos.
FI963717A7 (fi) Uusia mutatoituja viruksia, viruksenvastaisia yhdisteitä ja uusia menetelmiä rokotteiden valmistamiseksi
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ATE118353T1 (de) Rekombinanter herpes simplex gb-gd impfstoff.
IL104780A0 (en) Sulfonic acid derivatives in the treatment of viral diseases
ES2123753T3 (es) Vectores retroviricos para el tratamiento de tumores y lineas celulares que los contienen.
CO4480038A1 (es) Virus de inmunodeficiencia felina geneticamente alterados y vacuna eficaz contra las infecciones del virus de inmunodeficiencia felina
ES8800985A1 (es) Procedimiento de preparar proteinas.
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
ES8800358A1 (es) Un procedimiento para preparar un polipeptido hibrido.
DK631387D0 (da) Virusvektor
NO983375L (no) Retroviral vektor og anvendelse derav i genterapi
ES2191842T3 (es) Interleucina-8 como agente antiviral y antitumoral.
ES2104695T3 (es) Induccion de proteccion contra una infeccion virica.
ES8504248A1 (es) Procedimiento para la fabricacion de un plasmido recombinante que contiene un aminoacido
ES2195200T3 (es) Construccion de peptidos de rama multiples.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 245136

Country of ref document: ES